Vivimed Labs Limited receives approval for 3 products from its Hyderabad site

Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that it received approvals for 3 products from its state of the art manufacturing site in Hyderabad, which is PICS & Health Canada approved site.

1. Bilastine tablets 20mg under brand name FLUSTIN

Uses:

Bilastine is a second-generation antihistamine (a selective histamine H1 receptor antagonist).

It is used in the treatment of allergic Rhinoconjunctivitis and Urticaria (hives).

2. Ornidazole and Otloxacin tablets under brand name ORZOLE COMBI

Uses:

Ornidazole 500mg + Ofloxacin 200mg tablets is used in the treatment of bacterial & parasitic infections.

It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.

3. Paracetamol 125mg/5ml and Chlorpheniramine Maleate Syrup 2mg/5ml 100ml under brand name FEBRIL

Uses:

Paracetamol, also known as acetaminophen, is a medication used to treat fever and mild to moderate pain.

Chlorpheniramine Maleate, is an antihistamine used to treat the symptoms of allergic conditions such as allergic rhinitis.

Menthol is a topical analgesic. It works by temporarily relieving minor pain.

Commenting on the Approvals, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "These 3 approvals are testimony to high quality team work of Vivimed's end to end team. Branded exports is strategic thrust of 'New and Vibrant Vivimed'. The approvals are testimony to Vivimed's growth strategy".

Shares of VIVIMED LABS LTD. was last trading in BSE at Rs.17.25 as compared to the previous close of Rs. 16.75. The total number of shares traded during the day was 98923 in over 331 trades.

The stock hit an intraday high of Rs. 18.25 and intraday low of 16.2. The net turnover during the day was Rs. 1678186.

Source : Equity Bulls

Keywords